That we can designa nd synthesize glycoporphyrin-based compounds suitable as theranostics by combining the advantageous properties of different molecular scaffolds. Conjugation of af luorinated glucosea nalogue, in contrast to its non-fluorinated counterpart, to the porphyrin scaffold significantly increasedthe cellular uptake in cancerous cells. Moreover,the inherentfluorescenceoft he porphyrin and incorporation of fluorine, making the compounds act as 18 Fp ositron emission tomography tracers,a dd up to suitable diagnostic qualities with differentimaging modalities.
What new scientific questions/problems doest his work raise?
Severaln ew questionsc an be asked. For instance, 1) what is the selectivity of the fluoro-glycosylated porphyrins in ag reater variety of cancerc ell types, apart from melanoma?2 )What is the actual cytotoxic effect that can be achievedu sing photodynamic therapy, and how does it comparet om ore conventional photosensitizers?3 )How do the fluoro-glycosylated porphyrins behave in an in vivo model, and can this be determined with the corresponding PET tracer?4 )Can the porphyrin scaffold be equipped with other carbohydrates to achieve selectivity towards variable biological targets?
What future opportunities do you see (in the light of the results presented in this paper)?
We foresee that fluoro-glycoporphyrins can be highly useful therapeutics in photodynamic therapy,o wing to their superior properties of cellularu ptake and accumulationi nc ancer cells. In addition, by incorporating the radioactive fluorine-18 into the FDG moiety,aPET radiotracer can be obtained, which allows for simultaneouscancer diagnosis in clinic.
Is your current research mainly drivenb ycuriosity or rather applied? Our research is focused on possible diagnostic applications for the compoundst hat we develop. We are equally interested in how to efficiently synthesize novel compounds andtoevaluate their behavior in biological settings.T he curiosity and challenge to see how we can design and synthesize organic compoundwith specific properties in order to study and eventually effect disease related processes, for example, in cancer,i st he drivingf orce in our laboratory work.
Invited for this month'sc over picture is the group of Professor Peter Nilssona tt he Department of Physics, Chemistry and Biologya tL inkçping University (Sweden). The cover picture shows af luoro-glycoporphyrin that selectively targetsc ancer cells. The selectivity towards cancer cells are afforded due to proper functionalization of the porphyrin scaffold with specific carbohydrates, and the cancer cells can be visualized because of the intrinsic fluorescence from the porphyrin. The molecule also exhibitsproperties for photodynamic therapy and the incorporation of fluorine,int he form of 2-fluoro-2-deoxy glucose (FDG), offers the possibility to apply these compounds as 18F positron emission tomography( PET) tracers.T hus, fluoro-glycoporphyrins display multimodal properties and can be employed as theranostic agentst argeting cancer cells. Read the full text of their Full Paper at 10.1002/open.201800020.
